Loading clinical trials...

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial

NCT05296863•Dr. dr. Lili Legiawati, SpKK(K)

View on ClinicalTrials.gov

Summary

This study investigated the efficacy of adipose derived stem cell conditioned media (ADSC-CM) combined with minoxidil for hair regeneration therapy in male AGA.

Detailed Description

This study was a double-blind, randomized clinical trial (RCT). Two concentrations of ADSC-CM were utilized: concentrated and non-concentrated ADSC-CM. The scalp was divided vertically in half; one side was injected with 2 ml of ADSC-CM, while the control side received 2 ml of NaCl 0,9%. After the injection, patients applied topical 5% minoxidil twice daily. Clinical improvements were assessed using photographic evaluation and trichoscan every two weeks.

Eligibility

Age

25 - 58 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•males aged 25-58 years old
•Hamilton-Norwood criteria grades II to VI
•cessation of anti-androgens and minoxidil treatment for at least one month

Exclusion Criteria

•patients with hair loss other than AGA, such as alopecia areata, chemotherapy-induced alopecia, autoimmune-induced alopecia, and scalp malignancies;
•patients receiving 5-alpha reductase inhibitor therapy;
•patients who had received growth factor treatment (platelet-rich plasma or microneedling) for at least six months prior to the study; and
•history of hypertrophic scars or blood clotting disorders.

Locations (1)

Universitas Indonesia

Jakarta Pusat, Jakarta Special Capital Region, Indonesia

Key Dates

Start Date

October 11, 2021

Primary Completion Date

December 3, 2021

Completion Date

December 3, 2021

Last Updated

March 25, 2022

Enrollment

ACTUAL participants

Conditions

Alopecia, AndrogeneticHair Loss/Baldness

Interventions

Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil

COMBINATION_PRODUCT

Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil

COMBINATION_PRODUCT

Placebo and 5% Minoxidil

COMBINATION_PRODUCT

A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

NCT07011485

Alopecia, AndrogeneticBaldness+1 more

View study

COMPLETEDNA

Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss

NCT05970809

Male Pattern BaldnessAndrogenetic Alopecia+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 25, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

Inclusion Criteria

Exclusion Criteria

A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)